ADIAL PHARMACEUTICALS, INC. (ADIL)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

3.90 on 9 Oct 2026

5 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$7.98M

Free cash flow

$6.49M

Return on equity

-151.2%

Return on capital

-116.8%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
16 Jul 2026	Coastlands Capital LP 10% owner	Bought	$3.39K	0.3%
14 Jul 2026	Coastlands Capital LP 10% owner	Bought	$5.30K	0.5%
10 Jul 2026	Coastlands Capital LP 10% owner	Bought	$4.59K	0.4%
9 Jul 2026	Coastlands Capital LP 10% owner	Bought	$28.05K	2.7%
29 Jun 2026	Coastlands Capital LP 10% owner	Bought	$65.00K	7.2%
29 Sep 2023	Schuyler Kevin Director	Bought	$1.92K	opened

41out of 100

Profitability 0

Financial strength 70

Growth n/a

Insiders 65

Strongest on financial strength (70), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$106.33K

5 buys, 1 buyer

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan